A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma

Inclusion: * Histologically or cytologically-confirmed sarcoma of one of the following histologies: (1) Ewing's sarcoma / PNET; (2) rhabdomyosarcoma; (3) leiomyosarcoma; (4) adipocytic sarcoma; or (5) synovial sarcoma * Has measurable disease, at least one lesion ≥ 2 centimeters (cm) on conventional measurement techniques or ≥ 1 cm on spiral computed tomography (CT) scan * Has at least one measurable lesion located outside of a previously irradiated area * Has radiographic documentation of disease progression within 6 months prior to study entry * Has relapsed, refractory, and/or metastatic disease, incurable by surgery, radiotherapy, or other conventional systemic therapy * Been considered ineligible for systemic chemotherapy or received at least one previous regimen for relapsed, refractory, and/or metastatic disease * Adequate hematologic function * Has adequate hepatic function * Has adequate coagulation function * Has adequate renal function * Has fasting serum glucose \< 120 milligrams per deciliter (mg/dL) or below the upper limit of normal (ULN) * Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation Exclusion: * Has uncontrolled brain or leptomeningeal metastases * Not recovered to grade ≤ 1 from adverse events due to agents administered more than 3 weeks prior to study entry * Is receiving any other investigational …